Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and HHS. The company now faces a lawsuit from Novo Nordisk for patent infringement of its Wegovy pill.

Presented by the Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story Legal pressures mount for Hims & Hers over GLP-1 salesThe major

The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, birds insects, and other vermin.”

Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new oral weight loss medicine. | Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new oral weight loss medicine.

Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further downside in HIMS stock.

Hims & Hers last week announced a copycat version of the Wegovy pill that would cost $49 for the first month and $99 per month after on a five-month plan. That sent the stock surging last week, but shortly after the announcement, Novo Nordisk announced plans to sue Hims & Hers for patent infringement, which led the stock to give up those gains.

Hims & Hers is rated Hold as regulatory/legal risks hit its GLP-1 weight-loss pivot; resilient core & strong liquidity noted. Click to read more on HIMS stock.

Novo Nordisk’s (NVO) lawsuit is a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care. Once again, Big Pharma is weaponizing the US judicial system to limit consumer choice.